Changes in bone density and turnover after alendronate or estrogen withdrawal

• Published in: Menopause (New York, N.Y.) Vol. 11; no. 6, Part 1 of 2; pp. 622 - 630
• Main Authors: Wasnich, Richard D., Bagger, Yu Z., Hosking, David J., McClung, Michael R., Wu, Mei, Mantz, Ann Marie, Yates, John J., Ross, Philip D., Alexandersen, Peter, Ravn, Pernille, Christiansen, Claus, Santora, Arthur C.
• Format: Journal Article
• Language: English
• Published: United States The North American Menopause Society 01-11-2004
• Subjects: Aged; Alendronate - administration & dosage; Bone Density; Bone Remodeling; Double-Blind Method; Drug Administration Schedule; Estradiol - administration & dosage; Estrogen Replacement Therapy; Estrogens, Conjugated (USP) - administration & dosage; Female; Humans; Medroxyprogesterone Acetate - administration & dosage; Middle Aged; Norethindrone - administration & dosage; Norethindrone - analogs & derivatives; Osteoporosis, Postmenopausal - blood; Osteoporosis, Postmenopausal - drug therapy; Treatment Outcome
• ISSN: 1072-3714; 1530-0374
• DOI: 10.1097/01.GME.0000123641.76105.B5

OBJECTIVE:To compare bone mineral density (BMD) and bone turnover changes after therapy withdrawal in postmenopausal women treated with alendronate or estrogen-progestin.
DESIGN:In this randomized, blinded, multinational, placebo-controlled trial, 1,609 healthy postmenopausal women ages 45 to 59 years were assigned to receive alendronate, placebo, or open-label estrogen-progestin (conjugated equine estrogens plus medroxyprogesterone acetate or a cyclic regimen of 17β-estradiol, norethisterone acetate and estradiol). Of the original women, one third after year 2 and one third after year 4 were switched from alendronate to placebo, while remaining blinded to treatment assignment. The women taking estrogen-progestin in years 1 to 4 were followed off therapy in years 5 and 6. BMD at the lumbar spine and hip and biochemical markers of bone turnover were measured.
RESULTS:The treatment groups described in the current report represent 860 women at baseline; 481 women entered year 5, and 430 completed 6 years. BMD steadily decreased in the placebo group during all 6 years. In contrast, spine and hip BMD increased during the first 4 years in the groups receiving daily continuous alendronate 5 mg and estrogen-progestin. During years 5 and 6, BMD decreased at the lumbar spine -2.42% (95% CI = −4.10, −0.74) and total hip −1.09% (−2.60, 0.41) in the group previously treated with alendronate 5 mg for 4 years. In comparison, large BMD decreases were observed at the spine [−7.69% (−8.96, −6.41)] and total hip [−5.16% (−6.30, −4.01)] among women who had received estrogen-progestin for 4 years.
CONCLUSION:Alendronate produces greater residual skeletal effects than estrogen-progestin after therapy discontinuation.